Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexza Expects FDA, EU Regulatory Decisions On Adusave This December

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm has responded to a second “complete response” letter from FDA and to questions from EU regulators regarding its proposed inhalation formulation of antipsychotic loxapine.

Advertisement

Related Content

Alexza Finds New U.S. Marketing Partner For Adasuve In Teva
EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum
FDA Cmte. To Scrutinize Pulmonary Safety, REMS For Alexza's Inhaled Antipsychotic
Alexza's Inhaled Antipsychotic To Get Indication-Limiting REMS

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS074615

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel